Photo: Tasos Katopodis / Getty Images News / Getty Images
The White House has withdrawn the nomination of Dr. Heidi Overton to lead the Food and Drug Administration (FDA), just one day before a crucial Senate Health, Education, Labor and Pensions (HELP) Committee vote. Dr. Overton, nominated in August, faced opposition from both political parties, particularly concerning her positions on vaccines and abortion policy, as reported by Medical Economics.
Dr. Overton, who served as deputy director of the White House Domestic Policy Council, was nominated to replace Dr. Marty Makary, who resigned as commissioner in May. The Ritz Herald noted that her nomination was vulnerable due to the Republicans' narrow majority on the committee, which left the nomination at risk if any GOP member defected.
Senate HELP Committee Chairman Bill Cassidy expressed concerns about Dr. Overton's managerial experience and her support for breaking up combination vaccines, such as the measles, mumps, and rubella (MMR) shot, according to Medical Economics. Dr. Overton's confirmation process also included scrutiny over her stance on mifepristone, an abortion drug, and flavored vaping products.
The administration is now considering alternatives, including Senator Roger Marshall of Kansas, as a potential replacement, Investing.com reported. The FDA continues to operate under acting leadership, with Kyle Diamantas serving as acting commissioner since Dr. Makary's departure.
The withdrawal of Dr. Overton's nomination adds to the ongoing turnover in senior health-agency leadership. The FDA, which regulates products accounting for a significant share of U.S. consumer spending, has experienced substantial staff reductions since President Trump took office.